Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
18 12월 2023 - 9:00PM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing AI-powered precision T cell
therapies targeting clonal neoantigens to treat solid tumors, today
announced publication of a ‘Comment’ in Nature Cancer that outlines
the vast potential of neoantigen immunogenicity prediction,
discusses current limitations in the field that limit performance,
and proposes a path forward.
The article, entitled Breaking the performance
ceiling for neoantigen immunogenicity prediction, makes the case
that the efficient and accurate selection of immunogenic
neoantigens is a critical determinant in neoantigen-based
personalized tumor therapies. Selecting which neoantigens to use in
drug development based on their immunogenicity is crucial for
efficacy of personalized treatments as only a few neoantigens will
be clinically relevant.
The authors of the ‘Comment’ are all researchers
affiliated with the DECOD-Ag consortium of which Achilles
Therapeutics is a member. They note recent improvements in
computational immunogenicity-prediction models and suggest that the
performance of currently available artificial intelligence (AI)
methods for immunogenicity ranking will be surpassed by robust
prediction algorithms built from larger datasets with lower
bias.
Achilles has built a world-leading, AI-powered
PELEUS™ bioinformatics platform to identify clonal neoantigens from
each patient’s unique tumor profile. The proprietary PELEUS™
platform was developed and validated with sequence data from the
landmark TRACERx study led by Achilles co-founder Professor Charles
Swanton of the Crick Institute. Achilles has exclusive commercial
rights to the TRACERx study, which has generated one of the largest
data sets ever collected to analyze tumor evolution.
Earlier this year, the Company announced
analysis results showing that the new AI application of its PELEUS
bioinformatics platform, trained with proprietary real-world data,
outperformed current AI and non-AI state-of-the-art methods for
neoantigen immunogenicity prediction, enabling the identification
of the most potent clonal neoantigens for personalized cancer
therapies.
Co-author Dr Sergio Quezada, Chief
Scientific Officer of Achilles, commented: “Accurate
prediction of neoantigen immunogenicity can be pivotal in
determining the efficacy of immunological
treatments. It is therefore essential that we
collaborate to refine our prediction models and improve the
precision of our T cell therapies.”
About Achilles
TherapeuticsAchilles is a clinical-stage biopharmaceutical
company developing AI-Powered precision T cell therapies targeting
clonal neoantigens: protein markers unique to the individual that
are expressed on the surface of every cancer cell. The Company has
two ongoing Phase I/IIa trials, the CHIRON trial in patients with
advanced non-small cell lung cancer (NSCLC) and the THETIS trial in
patients with recurrent or metastatic melanoma. Achilles uses DNA
sequencing data from each patient, together with its proprietary
PELEUS™ bioinformatics platform, to identify clonal neoantigens
specific to that patient, and then develop precision T cell-based
product candidates specifically targeting those clonal
neoantigens.
Forward-Looking Statements
This press release contains express or implied
forward-looking statements that are based on our management's
belief and assumptions and on information currently available to
our management. Forward-looking statements in this press release
include, but are not limited to, statements regarding the timing of
the Company’s clinical and translational data updates and the
Company’s beliefs about recent data updates, and expectations
related to the Company’s operating expenses and capital expense
requirements. Although we believe that the expectations reflected
in these forward-looking statements are reasonable, these
statements relate to future events or our future operational or
financial performance, and involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance, or achievements to be materially different from any
future results, performance or achievements expressed or implied by
these forward-looking statements. The forward-looking statements in
this press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
For further information, please contact:
Investors:Meru AdvisorsLee M.
Sternlstern@meruadvisors.com
Media:ICR ConsiliumSukaina Virji, Tracy Cheung,
Emmalee Hoppe+44 (0) 203 709 5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Achilles Therapeutics (NASDAQ:ACHL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024